Abstract
This study evaluates the outcome of 66 pediatric patients with rrHL who underwent autoHSCT. Twenty-nine patients experienced early relapse, and 19 patients experienced late relapse. Of 18 newly diagnosed with HL, 13 were primary refractory disease and five had late responsive disease. At the time of transplantation, only 68% of the patients were chemosensitive. The majority of patients received BCNU + etoposide + ara-C + melphalan for conditioning (45/66), and peripheral blood (56/66) was used as a source of stem cells. After a median follow-up period of 39 months, 46 patients were alive. At five yr, the probabilities of OS, EFS, the relapse rate, and the non-relapse mortality rate were 63.1%, 54.3%, 36.4%, and 9.1%, respectively. The probability of EFS in chemosensitive and chemoresistant patients at five yr was 72.3% and 19%, respectively (p < 0.001). Multivariate analysis showed that chemoresistant disease at the time of transplantation was the only factor predicting limited both OS (hazard ratio = 4.073) and EFS (hazard ratio = 4.599). AutoHSCT plays an important role for the treatment of rrHL in children and adolescents, and survival rates are better for patients with chemosensitive disease at the time of transplantation.
References
Feb 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L LongoV T DeVita
Mar 1, 1985·Annals of Internal Medicine·T S HermanH S Kaplan
Jan 1, 1981·American Journal of Hematology·J R KanofskyJ E Ultmann
Apr 24, 1993·Lancet·D C LinchG V Hudson
Nov 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C D WilliamsG Meloni
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K S BakerP J Bierman
Feb 2, 2000·Bone Marrow Transplantation·A VerdeguerA Sastre
Feb 24, 2001·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·J FrankovichM R Verneris
May 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N L KobrinskyA T Meadows
Jun 28, 2002·Lancet·Norbert SchmitzUNKNOWN Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James B NachmanUNKNOWN Children's Cancer Group
Nov 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·YeeYie E LieskovskyRajni Agarwal
Nov 16, 2004·Journal of Pediatric Hematology/oncology·Sara StonehamUNKNOWN United Kingdom Children's Cancer Study Group
Sep 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Günther SchellongUNKNOWN DAL/GPOH
Oct 4, 2005·Pediatric Blood & Cancer·Robert S WimmerCindy L Schwartz
Nov 2, 2005·Pediatric Blood & Cancer·Melissa M Hudson
Aug 18, 2006·Bone Marrow Transplantation·D PetropoulosK W Chan
Jan 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sarah S DonaldsonMelissa M Hudson
Dec 18, 2007·Bone Marrow Transplantation·M B Bradley, M S Cairo
May 8, 2008·Current Treatment Options in Oncology·Michael R Olson, Sarah S Donaldson
Nov 26, 2008·Bone Marrow Transplantation·A ClaviezN Schmitz
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine Mauz-KörholzDieter Körholz
Jul 20, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Richard E HarrisMitchell S Cairo
Sep 13, 2012·British Journal of Haematology·Ann Y MinnKaryn A Goodman
Citations
Dec 1, 2017·Leukemia & Lymphoma·Lisa Giulino-RothFarid Boulad
Nov 11, 2017·Cancer·Regina M MyersPrakash Satwani
Jul 5, 2019·Pediatric Transplantation·Amr AbdallaAlaa El-Haddad
Nov 23, 2019·Journal of Global Oncology·Rabia WaliSaadiya Javed Khan